All In Biotech

Free tool

FAERS Monitor: Danziten

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 219293 or its brand name (Danziten, Nilotinib Tartrate). Reports on generic versions are filed under their own applications.

Reports

4,215

Serious

3,850

91% of reports

Hospitalization

835

Death reported

638

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug intolerance430
  • drug ineffective354
  • fatigue353
  • drug resistance349
  • diarrhoea344
  • dyspnoea338
  • nausea317
  • headache311
  • myalgia284
  • arthralgia282
  • abdominal pain274
  • pleural effusion274
  • pyrexia261
  • pruritus257
  • asthenia254

Reports by year received

View as table
YearReports
20074
200812
200917
201019
201143
201295
201388
2014154
2015157
2016215
2017177
2018267
2019440
2020375
2021347
2022323
2023306
2024365
2025386
2026425

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,944 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
drug resistanceSignal34968.762.122,934
pleural effusionSignal27422.620.15,616
drug intoleranceSignal43022.320.48,731
myalgiaSignal2848.37.51,841
abdominal painSignal2745.95.21,117
pyrexiaSignal2613.83.3536
arthralgiaSignal2823.43.0481
astheniaSignal2543.43.0429
pruritusSignal2573.33.0426
dyspnoeaSignal3383.02.7455
diarrhoeaSignal3442.72.4366
headacheSignal3112.52.2280
fatigueSignal3532.32.0257
nausea3172.01.8163
drug ineffective3541.31.232

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.